Detalhe da pesquisa
1.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657201
2.
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Am J Hematol
; 96(4): 418-427, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368455
3.
Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.
Proc Natl Acad Sci U S A
; 110(16): 6500-5, 2013 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23576741
4.
The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⺠T-cell lymphoma.
Mol Cancer
; 14: 53, 2015 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25884514
5.
NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.
J Pathol
; 230(1): 82-94, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23338972
6.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood Cancer J
; 14(1): 24, 2024 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307865
7.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Blood Adv
; 8(1): 194-206, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052042
8.
MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
Am J Pathol
; 180(5): 1772-80, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22414602
9.
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.
Front Oncol
; 12: 986305, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36276070
10.
Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.
Haematologica
; 96(6): 871-80, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21330319
11.
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Cancer Discov
; 11(6): 1440-1453, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33593877
12.
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.
Cancers (Basel)
; 12(7)2020 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32630797
13.
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood Cancer J
; 14(1): 40, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448422
14.
Type I insulin-like growth factor receptor signaling in hematological malignancies.
Oncotarget
; 8(1): 1814-1844, 2017 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27661006
15.
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
J Natl Cancer Inst
; 108(12)2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27576731
16.
SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
Neoplasia
; 17(9): 742-754, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26476082
17.
The ALK inhibitor ASP3026 eradicates NPM-ALK⺠T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
Oncotarget
; 5(14): 5750-63, 2014 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25026277
18.
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Oncotarget
; 5(21): 10280-92, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25373733
19.
Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.
Neoplasia
; 15(6): 669-83, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23730215